Table 2 Model of care

 Hospitalized at time of interview, N (%)

18 (41.9%)

74 (6.53%)

 Previously hospitalized during current phase, N (%)

7 (16.7%)

125 (11.0%)

  Times hospitalized during current phase, Mean (95% CI)

1.64 (0.83–2.45)

1.14 (1.04–1.23)

  Mean duration (days) hospitalized during current phase (95% CI)

91.4 (0–199.2)

12.9 (10.1–15.8)

  Median duration (days) hospitalized during current phase (IQR)

30 (26–102)

7 (5–14)

 Number of visits per episode: total (95% CI)

1093.4 (917–1269.8)

51.2 (42.1–60.3)

 Number of visits: DOT (95% CI)

614.5 (555.6–673.5)

167.6 (157.7–177.5)

 Number of visits: follow-up (95% CI)

10.9 (0–22.5)

3.7 (3.1–4.3)

 Number of visits: drug pick-up (95% CI)

569.1 (529.9–608.3)

9.1 (7.7–10.5)

 Number of visits pre-diagnosis (95% CI)

1.6 (0.9–2.2)

1.1 (1.1–1.2)

  Proportion of first visits to primary health facilities

5 (84.2%)

189 (39%)

  Proportion of first visits from private facilities

2 (28.8%)

159 (32.8%)

 Proportion of TB diagnoses made at private or NGO facility

2 (5%)

300 (26.5%)

 Treatment duration: intensive phase, weeks Mean (95% CI)

7 (6.1–7.9)

2 (2–2.1)

 Treatment duration: continuation phase, weeks Mean (95% CI)

14.8 (12.8–16.8)

4.1 (4.1–4.1)

Treatment delay (among new patients in intensive phase)

6

486

 Weeks of treatment delay Mean (95% CI)

9.5 (3.4–15.7)

9.9 (8.1–11.8)

 Proportion of patients with delay > 28 days (%)

3 (50.0%)

223 (45.9%)